Interestingly, ASXL1 mutants through their interaction with BRD4 were hypersensitive to bromodomain inhibitors (Yang et al., 2018), providing a potential treatment avenue for patients with these mutations in CML. Here, ASXL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.